Qiagen NV (NYSE:QGEN) Expected to Post Quarterly Sales of $390.24 Million

Wall Street analysts predict that Qiagen NV (NYSE:QGEN) will announce sales of $390.24 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Qiagen’s earnings. The lowest sales estimate is $384.14 million and the highest is $398.30 million. Qiagen reported sales of $377.91 million during the same quarter last year, which would suggest a positive year over year growth rate of 3.3%. The business is scheduled to issue its next earnings report on Monday, November 4th.

According to Zacks, analysts expect that Qiagen will report full year sales of $1.55 billion for the current financial year, with estimates ranging from $1.54 billion to $1.55 billion. For the next fiscal year, analysts expect that the firm will report sales of $1.69 billion, with estimates ranging from $1.67 billion to $1.70 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Qiagen.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, July 24th. The company reported $0.33 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.01). Qiagen had a net margin of 12.94% and a return on equity of 12.10%. The company had revenue of $381.60 million during the quarter, compared to the consensus estimate of $386.37 million. During the same quarter in the previous year, the company earned $0.33 earnings per share. The business’s revenue was up 1.2% on a year-over-year basis.

Several brokerages have issued reports on QGEN. Berenberg Bank reissued a “buy” rating and issued a $40.00 price target on shares of Qiagen in a research note on Friday, July 26th. Zacks Investment Research lowered Qiagen from a “hold” rating to a “sell” rating and set a $38.00 price target on the stock. in a research note on Tuesday. Goldman Sachs Group reissued a “buy” rating on shares of Qiagen in a research note on Thursday, August 1st. Barclays boosted their price target on Qiagen from $43.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, June 21st. Finally, Exane BNP Paribas raised Qiagen from a “neutral” rating to an “outperform” rating in a research note on Friday, July 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $41.67.

QGEN remained flat at $$36.34 during trading on Friday. The company’s stock had a trading volume of 470,472 shares, compared to its average volume of 1,177,853. Qiagen has a 12-month low of $32.33 and a 12-month high of $41.55. The company has a quick ratio of 1.59, a current ratio of 1.77 and a debt-to-equity ratio of 0.54. The business has a fifty day moving average price of $39.50. The stock has a market cap of $8.12 billion, a PE ratio of 27.12, a price-to-earnings-growth ratio of 2.27 and a beta of 0.83.

Large investors have recently modified their holdings of the company. Campbell & CO Investment Adviser LLC acquired a new position in shares of Qiagen during the first quarter worth approximately $229,000. PNC Financial Services Group Inc. raised its position in Qiagen by 1.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 205,337 shares of the company’s stock valued at $8,353,000 after buying an additional 3,609 shares during the last quarter. Cornerstone Advisors Inc. purchased a new stake in Qiagen in the 1st quarter valued at $44,000. Macquarie Group Ltd. purchased a new stake in Qiagen in the 4th quarter valued at $1,854,000. Finally, Martingale Asset Management L P raised its position in Qiagen by 2,044.8% in the 1st quarter. Martingale Asset Management L P now owns 494,619 shares of the company’s stock valued at $20,122,000 after buying an additional 471,558 shares during the last quarter. 62.45% of the stock is currently owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

See Also: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.